The ADAC technology
Strike pharma develops a novel next generation Antibody-Drug Conjugate (ADC) technology, the ADAC technology. ADACs are short for Adaptable Drug Affinity Conjugates and are built to improve deliver tailored made synthetic molecules to specific cell types for improved immune modulation. Our first drug candidate is within the IMMGAP platform aiming to transform personalized medicine within the immuno-oncology space. Using the IMMGAP platform, efficient delivery and prolonged half-life of patient tailored peptide therapeutics will ensure that the body becomes the factory, producing billions of T cells that can find and destroy tumors cells regardless of the location in the body.